pubmed-article:20693248 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20693248 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:20693248 | lifeskim:mentions | umls-concept:C0010674 | lld:lifeskim |
pubmed-article:20693248 | lifeskim:mentions | umls-concept:C0035203 | lld:lifeskim |
pubmed-article:20693248 | lifeskim:mentions | umls-concept:C0042491 | lld:lifeskim |
pubmed-article:20693248 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:20693248 | lifeskim:mentions | umls-concept:C1135662 | lld:lifeskim |
pubmed-article:20693248 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:20693248 | pubmed:dateCreated | 2011-4-1 | lld:pubmed |
pubmed-article:20693248 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20693248 | pubmed:abstractText | Outcome measures to assess therapeutic interventions in cystic fibrosis (CF) patients with mild lung disease are lacking. Our aim was to determine if the lung clearance index (LCI) can detect a treatment response to dornase alfa in paediatric CF patients with normal spirometry. CF patients between 6-18 yrs of age with FEV(1 )? 80% pred were eligible. In a crossover design, 17 patients received 4 weeks of dornase alfa and placebo in a randomised sequence separated by a 4-week washout period. The primary end-point was the change in LCI from dornase alfa versus placebo. A mixed model approach incorporating period-dependent baselines was used. The mean ± sd age was 10.32 ± 3.35 yrs. Dornase alfa improved LCI versus placebo (0.90 ± 1.44; p = 0.022). Forced expiratory flow at 25-75% expired volume measured by % pred and z-scores also improved in subjects on dornase alfa (6.1% ± 10.34%; p = 0.03 and 0.28 ± 0.46 z-score; p = 0.03). Dornase alfa significantly improved LCI. Therefore the LCI may be a suitable tool to assess early intervention strategies in this patient population. | lld:pubmed |
pubmed-article:20693248 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20693248 | pubmed:language | eng | lld:pubmed |
pubmed-article:20693248 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20693248 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20693248 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20693248 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20693248 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20693248 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20693248 | pubmed:month | Apr | lld:pubmed |
pubmed-article:20693248 | pubmed:issn | 1399-3003 | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:JensenRR | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:AminRR | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:GustafssonPP | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:LouWW | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:SubbaraoPP | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:RatjenFF | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:JabarAA | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:KerriganSS | lld:pubmed |
pubmed-article:20693248 | pubmed:author | pubmed-author:BalkovecSS | lld:pubmed |
pubmed-article:20693248 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20693248 | pubmed:volume | 37 | lld:pubmed |
pubmed-article:20693248 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20693248 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20693248 | pubmed:pagination | 806-12 | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:meshHeading | pubmed-meshheading:20693248... | lld:pubmed |
pubmed-article:20693248 | pubmed:year | 2011 | lld:pubmed |
pubmed-article:20693248 | pubmed:articleTitle | The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. | lld:pubmed |
pubmed-article:20693248 | pubmed:affiliation | Division of Respiratory Medicine, Dept of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada. reshma.amin@sickkids.ca | lld:pubmed |
pubmed-article:20693248 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:20693248 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:20693248 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:20693248 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20693248 | lld:pubmed |